4th Gen EGFR Inhibitor
2nd Gen SYK Inhibitor
We will see you at the J.P. Morgan 36th Annual Healthcare Conference in January 2018
> Press Release
Genosco’s pipelines consist of two assets in Phase I and multiple preclinical programs.
Genosco is an early clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.
Partnering with Genosco
We are always open to new potential opportunities to establish strategic collaborations to develop and market our product candidates.